Asset
CAMOTESKIMAB
Avalo Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04671251 | phase1 | completed | 2020-12-15 | 2022-03-30 | Avalo Therapeutics, Inc. | Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma |
FDA applications (0)
This company has no applications containing this asset.